Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) started the day on Wednesday, with a price decrease of -0.49% at $571.36, before settling in for the price of $574.16 at the close. Taking a more long-term approach, REGN posted a 52-week range of $520.50-$1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 22.10%. Meanwhile, its Annual Earning per share during the time was 15.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -21.87%. This publicly-traded company’s shares outstanding now amounts to $106.40 million, simultaneously with a float of $104.06 million. The organization now has a market capitalization sitting at $61.69 billion. At the time of writing, stock’s 50-day Moving Average stood at $613.57, while the 200-day Moving Average is $819.34.
Regeneron Pharmaceuticals, Inc (REGN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Regeneron Pharmaceuticals, Inc’s current insider ownership accounts for 3.61%, in contrast to 86.24% institutional ownership. According to the most recent insider trade that took place on Nov 01 ’24, this organization’s EVP Commercial sold 1,000 shares at the rate of 844.61, making the entire transaction reach 844,610 in total value, affecting insider ownership by 12,931.
Regeneron Pharmaceuticals, Inc (REGN) Earnings and Revenue Records
Regeneron Pharmaceuticals, Inc’s EPS decrease for this current 12-month fiscal period is -21.87% and is forecasted to reach 39.50 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.88% through the next 5 years, which can be compared against the 15.74% growth it accomplished over the previous five years trading on the market.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Let’s observe the current performance indicators for Regeneron Pharmaceuticals, Inc (REGN). It’s Quick Ratio in the last reported quarter now stands at 4.03. The Stock has managed to achieve an average true range (ATR) of 26.28. Alongside those numbers, its PE Ratio stands at $14.54, and its Beta score is 0.36. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.38. Similarly, its price to free cash flow for trailing twelve months is now 19.89.
In the same vein, REGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 39.29, a figure that is expected to reach 8.53 in the next quarter, and analysts are predicting that it will be 39.50 at the market close of one year from today.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
If we take a close look at the recent performances of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN), its last 5-days Average volume was 1.78 million that shows progress from its year to date volume of 1.07 million. During the previous 9 days, stock’s Stochastic %D was recorded 55.95% While, its Average True Range was 26.58.
Raw Stochastic average of Regeneron Pharmaceuticals, Inc (REGN) in the period of the previous 100 days is set at 22.33%, which indicates a major fall in contrast to 53.48% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.92% that was higher than 40.93% volatility it exhibited in the past 100-days period.
